SARS-CoV-2 Spike Antibodies
The SARS-CoV-2 spike protein remains the central target for vaccines, therapeutic antibodies, and serological assays, but ongoing viral evolution has introduced significant mutations—especially within the RBD—that can alter antibody binding and reduce neutralization potency. As circulating variants continue to diverge from the original 2020 spike, reliance on early-generation reagents is no longer sufficient. For research, diagnostics, and vaccine development, updated spike constructs and antibodies that maintain activity across variant lineages—or are specifically tailored to current sequences—are increasingly essential.
Recommended next Filters:
56 results
适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Delta, SARS CoV-2 Omicron
ELISA, Crys, SPR, IF
宿主: Human
Monoclonal
CR3022
unconjugated
Recombinant Antibody
8 references
1 validation
Independently Validated
适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa
ELISA, Crys, SPR, IF
宿主: 兔
Chimeric
CR3022
unconjugated
Recombinant Antibody
5 references
适用: SARS Coronavirus-2 (SARS-CoV-2)
ELISA
宿主: Camelid (Camelidae)
Monoclonal
Sb23
unconjugated
single-domain Antibody (sdAb)
Recombinant Antibody
You are here:
